Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog...

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Taking a hybrid qualitative-quantitative approach to research

Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video: https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr...

20th anniversary celebrations

We recently celebrated our 20th year anniversary with parties for our employees across the globe.Find out more and view the photos https://www.researchpartnership.com/news/2017/06/20th-anniversary-party-photos/

Pharma CI Asia Conference & Exhibition 2017

13-14 July 2017, Singapore

Director Richard Head is joint winner of the 2017 EphMRA President’s Award

We are delighted to announce that Research Partnership’s Richard Head is joint winner of the 2017 EphMRA President's Award for his contribution to pharmaceutical market research